Loading
CP
Collegium Pharmaceutical, Inc Stock: price and insider trades · United States
Collegium Pharmaceutical, Inc: what insiders have been doing
This page follows insider dealings at Collegium Pharmaceutical, Inc as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. In the past year (18 October 2025 to 18 October 2026), 20 filings came from 12 insiders.
No insider bought on the market over the period, while 5 insiders filed 6 sales totalling €3.4M. One trade stands out by size: a sale of €1.6M from Dreyer Scott, disclosed on 5 March 2026.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
For context, the typical company on the same exchange (median of 5,811 companies) published 19 filings over the same period, against 20 filings here. Our records for Collegium Pharmaceutical, Inc go back to 2016, with no purchases and 47 sales on the open market in total. The 10-K for the year ended 31 December 2025 shows 780.6 m USD of revenue and 62.9 m USD of net income.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
159
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€16M
47 ops. · all time
Who traded when
BuySaleDreyer Scott6 sales
Colleen Tupper5 sales
David Dieter2 sales
Freund John Gordon1 sale
Nancy Lurker1 sale
Rita J. Balice-Gordon1 sale
+2 other insiders
Analyst consensus: bullish or bearish?
Analysts rate Collegium Pharmaceutical, Inc Strong Buy (bullish), based on 8 analysts. Average price target: US$49.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 997 of 24,148 companies
80.0
score / 100
Value91
Quality69
FCF yld43%
Earn yld8.3%
EV/EBITDA3.9x
ROE18%
Gross mgn59%
Net mgn8.1%
Debt/EBITDA2.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$22.51
Analyst consensus
8 analystsStrong buy
US$43.00Target US$49.00(+118%)US$60.00
Income statement
RevenueUS$780.6M
Gross profitUS$463.3M59% margin
EBITDAUS$401M51% margin
Net incomeUS$62.9M5.9% margin
Valuation
PER (trailing)16.9x
PER (forward)3.1x
P/Book2.3x
Beta0.73
Balance sheet & cash
Market capUS$732.8M
Total debtUS$814.9M
Free Cash FlowUS$327.6M
Debt / Equity390%
Profitability & ownership
ROE17.6%
ROA5.8%
% insiders1.2%
% institutions130.8%
Last declaration on 30 September 2026
Declarations159 total
27,419 shares@ US$22.00370.086% mcap85.7% of flowCommonSEC144:0001959173-26-007152
13,920 shares@ US$35.73490.071% mcap48.0% of flowCommonSEC144:0001959173-26-005267
8,095 shares@ US$36.320.042% mcap28.4% of flowCommonSEC144:0001959173-26-005235
8,700 sharesCommon StockSEC:0001276038-26-000006:0
4,500 shares@ US$35.96910.018% mcap100.0% of flowCommon StockSEC:0001450485-26-000007:0
8,700 shares@ US$16.490.016% mcap44.2% of flowCommon StockSEC:0001254705-26-000002:0
8,840 shares@ US$35.7239.4% of flowCommon StockSEC:0002061438-26-000009:0
13,976 shares@ US$34.924160.6% of flowCommon StockSEC:0002061438-26-000006:0
6,224 shares@ US$36.65100.0% of flowCommon StockSEC:0002061438-26-000004:0
46,417 shares@ US$40.363625.5% of flowCommon StockSEC:0001746251-26-000004:0
22,194 shares0Common StockSEC:0002061438-26-000002:0
26,421 shares0Common StockSEC:0001862082-26-000002:0
14,268 shares0Common StockSEC:0001748462-26-000002:0
19,023 shares0Common StockSEC:0001746251-26-000002:0
79,264 shares0Common StockSEC:0001699488-26-000002:0
17,600 shares@ US$15.903.8% of flowCommon StockSEC:0001746251-25-000004:0
3,650 shares@ US$47.0338100.0% of flowCommon StockSEC:0001825625-25-000004:0
8,983 shares@ US$47.35100.0% of flowCommon StockSEC:0001699488-25-000004:0
15,000 shares@ US$16.4923.6% of flowCommon StockSEC:0001560152-25-000004:0
25,142 shares@ US$40.380132.9% of flowCommon StockSEC:0001862082-25-000004:0
17,478 shares@ US$38.424162.1% of flowCommon StockSEC:0001062993-25-015277:0
16,389 shares@ US$21.344.8% of flowCommon StockSEC:0001062993-25-014766:0
15,000 shares@ US$13.45100.0% of flowCommon StockSEC:0001062993-25-014694:0
25,000 shares@ US$37.85100.0% of flowCommon Stock, par value $0.001 per shareSEC:0000902664-25-003729:0
4,861 shares@ US$21.34100.0% of flowCommon StockSEC:0001062993-25-014526:0
25 of 159 declarations
About Collegium Pharmaceutical, Inc
Collegium Pharmaceutical, Inc. is a U.S.-listed biopharmaceutical company trading on the NASDAQ under the ticker COLL. Its headquarters are in Stoughton, Massachusetts, United States. Collegium is best described as a specialty pharma company with a focused commercial model built around differentiated prescription medicines rather than broad early-stage discovery. Founded in the early 2000s, the company has evolved through a combination of in-house development, portfolio expansion, and targeted acquisitions.
Collegium’s historical core has been pain management, an area that remains highly regulated and commercially specialized. Its key products include Xtampza ER, an abuse-deterrent extended-release oxycodone formulation built on proprietary technology; Belbuca, a buprenorphine buccal film for severe chronic pain; and the Nucynta franchise, which includes tapentadol products for immediate- and extended-release use. More recently, the company has added a meaningful ADHD growth platform through Jornay PM, a delayed-release/extended-release methylphenidate product designed for evening dosing. That portfolio mix gives Collegium a more balanced revenue base than a pure single-asset story, although the company still remains concentrated in a relatively small number of commercial brands.
Read moreShow less
From a competitive standpoint, Collegium occupies a niche position versus larger diversified pharmaceutical peers. Its strengths lie in formulation science, controlled-substance commercialization, payer/access execution, and a specialized sales model focused on prescribers in pain and, increasingly, attention disorders. In pain, Collegium competes with much larger branded and generic players, but its products are differentiated by dosage form, abuse-deterrence features, and patient use case. This can support resilience in specific segments, but it also leaves the business exposed to prescription trends, regulatory scrutiny, pricing pressure, and portfolio concentration risk.
Recent company developments have been notable. In 2025 and early 2026, Collegium reported continued revenue growth, strong performance from Jornay PM, and solid contributions from its pain portfolio. The company also closed a $980 million syndicated credit facility, signaling active capital structure management. Another major strategic step came in March 2026, when Collegium announced the acquisition of AZSTARYS from Corium Therapeutics, strengthening its ADHD presence and extending its growth runway. Collegium has also continued to work on commercial partnerships, including arrangements related to authorized generics for the Nucynta franchise. For investors, COLL is a NASDAQ-listed United States healthcare name with a specialty-pharma profile, combining mature franchise durability with selective growth opportunities in pain and ADHD.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
